Product Name |
Ganirelix Impurity B |
Alternate Names |
Ganirelix Impurities, Impurities of Ganirelix |
CAT No. |
CS-P-01380
|
CAS No. |
Not Available |
Category |
Impurities |
Stock |
IN-Stock
|
Mol. Wt. |
936.48 g/mol |
Mol. For. |
C51H58ClN5O10
|
Hazardous |
This is not a Hazardous Compound
|
COA |
View Sample COA
|
MSDS |
View Sample MSDS
|
Parent API |
Ganirelix |
Therapeutic |
Synthetic Peptides |
Controlled |
No |
Shipping |
Free for purchase above 1000$ |
Delivery |
In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
Return |
Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
Ordering |
Place your order online or by email sales@clearsynth.com |
If you find a better price anywhere else we guarantee Price match.
Ganirelix Impurity B is a chemical compound that is used in the pharmaceutical industry to manufacture the drug Ganirelix. Ganirelix is a synthetic decapeptide that is used to treat infertility in women by inhibiting the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Ganirelix Impurity B is an impurity that is formed during the manufacturing of Ganirelix, and it is important to control its levels during the manufacturing process as it can affect the quality and purity of the final product.
Chemically, Ganirelix Impurity B is a peptide that contains 10 amino acids. It has a molecular formula of C54H83N15O14 and a molecular weight of 1164.4 g/mol. Its chemical structure is similar to that of Ganirelix, but it contains an additional amino acid residue. Ganirelix Impurity B is classified as a peptide impurity and is considered to be a minor impurity in the manufacturing process of Ganirelix.
During the manufacturing process of Ganirelix, it is important to control the levels of Ganirelix Impurity B as it can affect the potency and purity of the final product. The presence of Ganirelix Impurity B can also affect the stability of the final product, leading to a shorter shelf life. Therefore, pharmaceutical companies must ensure that the levels of Ganirelix Impurity B are within acceptable limits to ensure the quality and efficacy of the final product.